0000000000645028

AUTHOR

Ylenia Perone

0000-0002-6390-0327

showing 1 related works from this author

Effect of Cabergoline on Metabolism in Prolactinomas.

2013

<b><i>Introduction:</i></b> Hyperprolactinemia has been implicated in the pathogenesis of obesity and glucose intolerance and is reportedly associated with an impaired metabolic profile. The current study aimed at investigating the effects of 12- and 60-month treatment with cabergoline (CAB) on metabolic syndrome (MetS) in patients with prolactinomas. <b><i>Patients and Methods:</i></b> 61 patients with prolactinomas (13 men, 48 women, 41 with microadenoma, 20 with macroadenoma), aged 34.4 ± 10.3 years, entered the study. In all patients, prolactin (PRL) and metabolic parameters were assessed at diagnosis and after 12 and 60 months of continuo…

AdultMalemedicine.medical_specialtyTime FactorsEndocrinology Diabetes and MetabolismTreatment outcomeprolactinomasAntineoplastic AgentsSettore MED/13 - EndocrinologiaPathogenesisCellular and Molecular NeuroscienceEndocrinologyInsulin resistanceMetabolic DiseasesCabergolineInternal medicinePrevalenceMedicineHumansInsulinPituitary NeoplasmsProspective StudiesErgolinesAdiposityMetabolic SyndromeDose-Response Relationship DrugEndocrine and Autonomic Systemsbusiness.industryPituitary tumorsMetabolismFastingmedicine.diseasePrognosisProlactinProlactinHyperprolactinemiaEndocrinologyTreatment OutcomeprolactinomacabergolineFemaleMetabolic syndromeInsulin Resistancebusinessmetabolismmedicine.drug
researchProduct